240 related articles for article (PubMed ID: 24597515)
1. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations.
Hassan-Mohamed I; Giorgio C; Incerti M; Russo S; Pala D; Pasquale EB; Zanotti I; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A; Tognolini M
Br J Pharmacol; 2014 Dec; 171(23):5195-208. PubMed ID: 24597515
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction.
Giorgio C; Incerti M; Corrado M; Rusnati M; Chiodelli P; Russo S; Callegari D; Ferlenghi F; Ballabeni V; Barocelli E; Lodola A; Tognolini M
Biochem Pharmacol; 2018 Jan; 147():21-29. PubMed ID: 29129483
[TBL] [Abstract][Full Text] [Related]
3. Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation.
Giorgio C; Hassan Mohamed I; Flammini L; Barocelli E; Incerti M; Lodola A; Tognolini M
PLoS One; 2011 Mar; 6(3):e18128. PubMed ID: 21479221
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships and mechanism of action of Eph-ephrin antagonists: interaction of cholanic acid with the EphA2 receptor.
Tognolini M; Incerti M; Hassan-Mohamed I; Giorgio C; Russo S; Bruni R; Lelli B; Bracci L; Noberini R; Pasquale EB; Barocelli E; Vicini P; Mor M; Lodola A
ChemMedChem; 2012 Jun; 7(6):1071-83. PubMed ID: 22529030
[TBL] [Abstract][Full Text] [Related]
5. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis.
Giorgio C; Russo S; Incerti M; Bugatti A; Vacondio F; Barocelli E; Mor M; Pala D; Hassan-Mohamed I; Gioiello A; Rusnati M; Lodola A; Tognolini M
Biochem Pharmacol; 2016 Jan; 99():18-30. PubMed ID: 26462575
[TBL] [Abstract][Full Text] [Related]
6. Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists.
Tognolini M; Incerti M; Pala D; Russo S; Castelli R; Hassan-Mohamed I; Giorgio C; Lodola A
ChemMedChem; 2014 Jan; 9(1):67-72. PubMed ID: 24115725
[TBL] [Abstract][Full Text] [Related]
7. Comparative Analysis of Virtual Screening Approaches in the Search for Novel EphA2 Receptor Antagonists.
Callegari D; Pala D; Scalvini L; Tognolini M; Incerti M; Rivara S; Mor M; Lodola A
Molecules; 2015 Sep; 20(9):17132-51. PubMed ID: 26393553
[TBL] [Abstract][Full Text] [Related]
8. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
Wykosky J; Debinski W
Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
[TBL] [Abstract][Full Text] [Related]
9. The Functions of EphA1 Receptor Tyrosine Kinase in Several Tumors.
Wu Y; Du Z; Mou J; Qiu X; Chen J; Cai S; Ren D; Xiao F; Zhou G; Yuan C
Curr Med Chem; 2023; 30(20):2340-2353. PubMed ID: 35996244
[TBL] [Abstract][Full Text] [Related]
10. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization.
Ogawa K; Pasqualini R; Lindberg RA; Kain R; Freeman AL; Pasquale EB
Oncogene; 2000 Dec; 19(52):6043-52. PubMed ID: 11146556
[TBL] [Abstract][Full Text] [Related]
11. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng N; Brantley DM; Liu H; Lin Q; Enriquez M; Gale N; Yancopoulos G; Cerretti DP; Daniel TO; Chen J
Mol Cancer Res; 2002 Nov; 1(1):2-11. PubMed ID: 12496364
[TBL] [Abstract][Full Text] [Related]
12. Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.
Incerti M; Tognolini M; Russo S; Pala D; Giorgio C; Hassan-Mohamed I; Noberini R; Pasquale EB; Vicini P; Piersanti S; Rivara S; Barocelli E; Mor M; Lodola A
J Med Chem; 2013 Apr; 56(7):2936-47. PubMed ID: 23489211
[TBL] [Abstract][Full Text] [Related]
13. Metadynamics for Perspective Drug Design: Computationally Driven Synthesis of New Protein-Protein Interaction Inhibitors Targeting the EphA2 Receptor.
Incerti M; Russo S; Callegari D; Pala D; Giorgio C; Zanotti I; Barocelli E; Vicini P; Vacondio F; Rivara S; Castelli R; Tognolini M; Lodola A
J Med Chem; 2017 Jan; 60(2):787-796. PubMed ID: 28005388
[TBL] [Abstract][Full Text] [Related]
14. Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction.
Pala D; Castelli R; Incerti M; Russo S; Tognolini M; Giorgio C; Hassan-Mohamed I; Zanotti I; Vacondio F; Rivara S; Mor M; Lodola A
J Chem Inf Model; 2014 Oct; 54(10):2621-6. PubMed ID: 25289483
[TBL] [Abstract][Full Text] [Related]
15. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.
Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB
J Biol Chem; 2008 Oct; 283(43):29461-72. PubMed ID: 18728010
[TBL] [Abstract][Full Text] [Related]
16. Engineering nanomolar peptide ligands that differentially modulate EphA2 receptor signaling.
Gomez-Soler M; Petersen Gehring M; Lechtenberg BC; Zapata-Mercado E; Hristova K; Pasquale EB
J Biol Chem; 2019 May; 294(22):8791-8805. PubMed ID: 31015204
[TBL] [Abstract][Full Text] [Related]
17. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach.
Ferrari FR; Giorgio C; Zappia A; Ballabeni V; Bertoni S; Barocelli E; Scalvini L; Galvani F; Mor M; Lodola A; Tognolini M
Biochem Pharmacol; 2023 Mar; 209():115452. PubMed ID: 36792038
[TBL] [Abstract][Full Text] [Related]
19. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of EphA2 by Dasatinib Suppresses Radiation-Induced Intestinal Injury.
Kim A; Seong KM; Choi YY; Shim S; Park S; Lee SS
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33265912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
